[
  {
    "ts": null,
    "headline": "Business Lookahead: US inflation reading, China's GDP figures",
    "summary": "STORY: From a crucial U.S. inflation reading to GDP figures from China, these are the stories to watch in business and finance in the coming week.:: Look Ahead:: Tariff testJune’s consumer price index, due on Tuesday, will offer Wall Street clues on when the Federal Reserve may next cut interest rates.Recent minutes from the Fed’s June meeting showed most officials remain worried about inflationary pressure they expect from Trump’s tariffs.Fed fund futures indicate a slim chance of a rate cut at the end of July meeting, but suggest easing in September is likely.It comes as corporate reports in the first earnings quarter under these tariff wars are due.Major banks like JPMorgan Chase, Bank of America and Wells Fargo will report in the coming week.Results from Netflix, Johnson & Johnson and 3M are also expected.:: Europe’s second-quarter earningsSecond-quarter earnings also kick off in Europe.STOXX 600 earnings are expected to fall 0.2% after last quarter’s 2.2% growth.Forward guidance will be key to understanding the fallout from this era of tariffs and fears of more levies.Though it's not obvious when looking at market performance: the S&P 500 is scaling new record highs and bourses in Europe – including Frankfurt and London – are hovering near previous peaks.:: Stimulating spendingChina’s GDP figures due on Tuesday are tipped to show the economy still chugging along above the government’s soft target of 5%-ish growth.But same-day retail sales numbers should reinforce that consumers are still saving instead of spending, frustrating government efforts to gear the economy towards consumption.With the politburo due to meet around the end of the month, hopes are high for more stimulus to come.:: A test of relevanceG20 finance ministers and central bankers gather in South Africa’s Durban starting on Thursday.The meeting comes amid growing questions over the group’s effectiveness on stalled progress on debt relief, climate finance and access to capital for developing nations.U.S. Treasury Secretary Scott Bessent will skip the gathering.",
    "url": "https://finnhub.io/api/news?id=63a4cf4d20035e2f7a10e57846e1133d611071811f95b37e9394d2d04586e21a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752271251,
      "headline": "Business Lookahead: US inflation reading, China's GDP figures",
      "id": 135886516,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "STORY: From a crucial U.S. inflation reading to GDP figures from China, these are the stories to watch in business and finance in the coming week.:: Look Ahead:: Tariff testJune’s consumer price index, due on Tuesday, will offer Wall Street clues on when the Federal Reserve may next cut interest rates.Recent minutes from the Fed’s June meeting showed most officials remain worried about inflationary pressure they expect from Trump’s tariffs.Fed fund futures indicate a slim chance of a rate cut at the end of July meeting, but suggest easing in September is likely.It comes as corporate reports in the first earnings quarter under these tariff wars are due.Major banks like JPMorgan Chase, Bank of America and Wells Fargo will report in the coming week.Results from Netflix, Johnson & Johnson and 3M are also expected.:: Europe’s second-quarter earningsSecond-quarter earnings also kick off in Europe.STOXX 600 earnings are expected to fall 0.2% after last quarter’s 2.2% growth.Forward guidance will be key to understanding the fallout from this era of tariffs and fears of more levies.Though it's not obvious when looking at market performance: the S&P 500 is scaling new record highs and bourses in Europe – including Frankfurt and London – are hovering near previous peaks.:: Stimulating spendingChina’s GDP figures due on Tuesday are tipped to show the economy still chugging along above the government’s soft target of 5%-ish growth.But same-day retail sales numbers should reinforce that consumers are still saving instead of spending, frustrating government efforts to gear the economy towards consumption.With the politburo due to meet around the end of the month, hopes are high for more stimulus to come.:: A test of relevanceG20 finance ministers and central bankers gather in South Africa’s Durban starting on Thursday.The meeting comes amid growing questions over the group’s effectiveness on stalled progress on debt relief, climate finance and access to capital for developing nations.U.S. Treasury Secretary Scott Bessent will skip the gathering.",
      "url": "https://finnhub.io/api/news?id=63a4cf4d20035e2f7a10e57846e1133d611071811f95b37e9394d2d04586e21a"
    }
  },
  {
    "ts": null,
    "headline": "Big pharma's multiple looming patent cliffs: What to know",
    "summary": "The pharmaceutical industry is staring down a major patent cliff, with key drugs from Merck (MRK), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ) set to lose exclusivity by 2030. Yahoo Finance Senior Reporter Anjalee Khemlani and Freedom Capital Markets chief global strategist Jay Woods join Market Domination host Josh Lipton to discuss the industry's risks and how Wall Street is responding. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=6c19949832175d329a0625c8a4547b90492148f57fabbb3a53416d99530dda68",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752267366,
      "headline": "Big pharma's multiple looming patent cliffs: What to know",
      "id": 135885558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The pharmaceutical industry is staring down a major patent cliff, with key drugs from Merck (MRK), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ) set to lose exclusivity by 2030. Yahoo Finance Senior Reporter Anjalee Khemlani and Freedom Capital Markets chief global strategist Jay Woods join Market Domination host Josh Lipton to discuss the industry's risks and how Wall Street is responding. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=6c19949832175d329a0625c8a4547b90492148f57fabbb3a53416d99530dda68"
    }
  },
  {
    "ts": null,
    "headline": "Pre-Markets Red on Trump's Tariff Threats to Canada",
    "summary": "Pre-Markets Red on Trump's Tariff Threats to Canada.",
    "url": "https://finnhub.io/api/news?id=55dbc31cf4adec117c05e3cc2bdce72a721f517553081c82795dcbabbfa05ec2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752246600,
      "headline": "Pre-Markets Red on Trump's Tariff Threats to Canada",
      "id": 135883371,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Pre-Markets Red on Trump's Tariff Threats to Canada.",
      "url": "https://finnhub.io/api/news?id=55dbc31cf4adec117c05e3cc2bdce72a721f517553081c82795dcbabbfa05ec2"
    }
  },
  {
    "ts": null,
    "headline": "New Tariff Talk Sends Pre-Markets Off Record Highs",
    "summary": "President Trump announced a new +35% tariff on all Canadian goods imported to the U.S. this morning. Pre-markets are now in the red.",
    "url": "https://finnhub.io/api/news?id=b4e4eb2e446aafc87035b23e8a506f01cc35b3321fc7586d1ff1d9dd536a383c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752244440,
      "headline": "New Tariff Talk Sends Pre-Markets Off Record Highs",
      "id": 135883374,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "President Trump announced a new +35% tariff on all Canadian goods imported to the U.S. this morning. Pre-markets are now in the red.",
      "url": "https://finnhub.io/api/news?id=b4e4eb2e446aafc87035b23e8a506f01cc35b3321fc7586d1ff1d9dd536a383c"
    }
  },
  {
    "ts": null,
    "headline": "Bayer Wins Hormone-Free Treatment Approval for Women in the UK",
    "summary": "BAYRY secures first global approval for Lynkuet in the UK, a hormone-free treatment for menopause-related hot flashes.",
    "url": "https://finnhub.io/api/news?id=634cb9a693750ac030ecf39c5879044605ba1ccde10e35d7cfb793588b787c6f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752243000,
      "headline": "Bayer Wins Hormone-Free Treatment Approval for Women in the UK",
      "id": 135882033,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "BAYRY secures first global approval for Lynkuet in the UK, a hormone-free treatment for menopause-related hot flashes.",
      "url": "https://finnhub.io/api/news?id=634cb9a693750ac030ecf39c5879044605ba1ccde10e35d7cfb793588b787c6f"
    }
  },
  {
    "ts": null,
    "headline": "Unveiling Johnson & Johnson (JNJ) Q2 Outlook: Wall Street Estimates for Key Metrics",
    "summary": "Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Johnson & Johnson (JNJ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.",
    "url": "https://finnhub.io/api/news?id=119a9b0931c395aa42b0453a311851a7c1ff557117d38c41a7e154b795e7a4b8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752239704,
      "headline": "Unveiling Johnson & Johnson (JNJ) Q2 Outlook: Wall Street Estimates for Key Metrics",
      "id": 135883463,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Johnson & Johnson (JNJ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.",
      "url": "https://finnhub.io/api/news?id=119a9b0931c395aa42b0453a311851a7c1ff557117d38c41a7e154b795e7a4b8"
    }
  },
  {
    "ts": null,
    "headline": "Alvotech: A Fast-Expanding Biosimilar Concern",
    "summary": "Alvotech stock has dropped despite strong fundamentals and rapid sales growth. Read about ALVO's projected revenue, debt concerns, and tariff challenges.",
    "url": "https://finnhub.io/api/news?id=18e00e0ea56521085f094ca75a7d197bbe2781e2c3c86c5b423335ca89a4e85a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752238167,
      "headline": "Alvotech: A Fast-Expanding Biosimilar Concern",
      "id": 135882391,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1456995360/image_1456995360.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Alvotech stock has dropped despite strong fundamentals and rapid sales growth. Read about ALVO's projected revenue, debt concerns, and tariff challenges.",
      "url": "https://finnhub.io/api/news?id=18e00e0ea56521085f094ca75a7d197bbe2781e2c3c86c5b423335ca89a4e85a"
    }
  },
  {
    "ts": null,
    "headline": "TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?",
    "summary": "TEVA stock jumps 21.6% in three months on branded drug growth, biosimilar launches, and margin-boosting cost cuts.",
    "url": "https://finnhub.io/api/news?id=b655be281d0abc34024adecbfd5884754e9912f9a3150923465be1a5971e5153",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752237060,
      "headline": "TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?",
      "id": 135879297,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "TEVA stock jumps 21.6% in three months on branded drug growth, biosimilar launches, and margin-boosting cost cuts.",
      "url": "https://finnhub.io/api/news?id=b655be281d0abc34024adecbfd5884754e9912f9a3150923465be1a5971e5153"
    }
  },
  {
    "ts": null,
    "headline": "Mar Vista U.S. Quality Q2 2025 Top Contributors And Detractors",
    "summary": "Microsoft, Broadcom, and Oracle were among the portfolioâs top contributors for the quarter.",
    "url": "https://finnhub.io/api/news?id=b74aec12eeecd3da64974060d0f93e5fd5a51dc931d1c27670b4863d507ed603",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752235260,
      "headline": "Mar Vista U.S. Quality Q2 2025 Top Contributors And Detractors",
      "id": 135882094,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2199011911/image_2199011911.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Microsoft, Broadcom, and Oracle were among the portfolioâs top contributors for the quarter.",
      "url": "https://finnhub.io/api/news?id=b74aec12eeecd3da64974060d0f93e5fd5a51dc931d1c27670b4863d507ed603"
    }
  },
  {
    "ts": null,
    "headline": "3 AI-Driven Medical Device Stocks to Watch in 2025",
    "summary": "BSX, JNJ and GEHC are leveraging AI to boost device performance, diagnostics and surgical precision in 2025.",
    "url": "https://finnhub.io/api/news?id=c97adffae0350f8aaec32229c4c4ff9816febee288570b97bc6393284b99982b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752235200,
      "headline": "3 AI-Driven Medical Device Stocks to Watch in 2025",
      "id": 135880614,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "BSX, JNJ and GEHC are leveraging AI to boost device performance, diagnostics and surgical precision in 2025.",
      "url": "https://finnhub.io/api/news?id=c97adffae0350f8aaec32229c4c4ff9816febee288570b97bc6393284b99982b"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Declined Amid Broad Sell-Off in Healthcare",
    "summary": "Mar Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Premier Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The first half of 2025 concluded on a remarkable note, with U.S. stocks bouncing back from earlier volatility to reach new record highs. The S&P […]",
    "url": "https://finnhub.io/api/news?id=1ce187b8bd4609331d91a9c88636ea688618ae88117a0dde652240502e1a4bd7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752234523,
      "headline": "Johnson & Johnson (JNJ) Declined Amid Broad Sell-Off in Healthcare",
      "id": 135877168,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Mar Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Premier Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The first half of 2025 concluded on a remarkable note, with U.S. stocks bouncing back from earlier volatility to reach new record highs. The S&P […]",
      "url": "https://finnhub.io/api/news?id=1ce187b8bd4609331d91a9c88636ea688618ae88117a0dde652240502e1a4bd7"
    }
  },
  {
    "ts": null,
    "headline": "Intuitive Surgical: A Leadership That Is Hard To Extirpate",
    "summary": "Intuitive Surgical: A Leadership That Is Hard To Extirpate",
    "url": "https://finnhub.io/api/news?id=bb375eda9bcbe1cf29bd9fb6bf26310197292ab9beadcd9171ad8bef432981f8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752233818,
      "headline": "Intuitive Surgical: A Leadership That Is Hard To Extirpate",
      "id": 135881537,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=bb375eda9bcbe1cf29bd9fb6bf26310197292ab9beadcd9171ad8bef432981f8"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to watch next week: Goldman Sachs, Netflix, TSMC, ASML and Burberry",
    "summary": "Earnings preview of key companies reporting in the coming week and what to look out for.",
    "url": "https://finnhub.io/api/news?id=50318dc9bef322c6bb1b2ed0f642589c1d04f102da3a1a6486f872362233ee4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752233713,
      "headline": "Stocks to watch next week: Goldman Sachs, Netflix, TSMC, ASML and Burberry",
      "id": 135874670,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Earnings preview of key companies reporting in the coming week and what to look out for.",
      "url": "https://finnhub.io/api/news?id=50318dc9bef322c6bb1b2ed0f642589c1d04f102da3a1a6486f872362233ee4e"
    }
  },
  {
    "ts": null,
    "headline": "Ulcerative Colitis Drug Market Analysis and Forecast, 2025-2035 | Anti-TNF a Agents and Interleukin Antagonists Spearhead Therapeutic Developments",
    "summary": "Ulcerative colitis, a chronic inflammatory bowel disease, presents treatment challenges due to its variable symptoms and unpredictable flare-ups. The global market is set to grow, driven by biologic treatments like monoclonal antibodies and immunomodulators. Market segmentation by drug class includes Anti-TNF α agents and interleukin antagonists, each offering distinct benefits. North America leads the market with established healthcare infrastructure. Key growth drivers are the rising incidence",
    "url": "https://finnhub.io/api/news?id=c1ac3bb63e87f8a640eb5ce87d00de4c05358a5d56e3d49fcd1edd8e902cdb8e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752221100,
      "headline": "Ulcerative Colitis Drug Market Analysis and Forecast, 2025-2035 | Anti-TNF a Agents and Interleukin Antagonists Spearhead Therapeutic Developments",
      "id": 135877171,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Ulcerative colitis, a chronic inflammatory bowel disease, presents treatment challenges due to its variable symptoms and unpredictable flare-ups. The global market is set to grow, driven by biologic treatments like monoclonal antibodies and immunomodulators. Market segmentation by drug class includes Anti-TNF α agents and interleukin antagonists, each offering distinct benefits. North America leads the market with established healthcare infrastructure. Key growth drivers are the rising incidence",
      "url": "https://finnhub.io/api/news?id=c1ac3bb63e87f8a640eb5ce87d00de4c05358a5d56e3d49fcd1edd8e902cdb8e"
    }
  },
  {
    "ts": null,
    "headline": "Psoriatic Arthritis Market Report 2025-2035 | Competitive Analysis of AbbVie, UCB, Pfizer, Johnson & Johnson, Eli Lilly and Co, Bristol-Myers Squibb, Affibody, Amgen, Boehringer Ingelheim, Sun Pharma",
    "summary": "Psoriatic arthritis is a chronic inflammatory disease linked to psoriasis, characterized by joint inflammation, pain, and swelling. Affecting both men and women, typically between ages 30-50, it's driven by rising autoimmune diseases and emerging biologic treatments like TNF and JAK inhibitors. Key market developments include advances in early diagnosis tools and precision medicine, tailoring treatments to genetic profiles. While growth is challenged by high biologic costs and diagnosis complexi",
    "url": "https://finnhub.io/api/news?id=6d6c2f9bc2075c0b32e4585440d25a0af4a43c7f00592f693f00f0d680f64571",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752220860,
      "headline": "Psoriatic Arthritis Market Report 2025-2035 | Competitive Analysis of AbbVie, UCB, Pfizer, Johnson & Johnson, Eli Lilly and Co, Bristol-Myers Squibb, Affibody, Amgen, Boehringer Ingelheim, Sun Pharma",
      "id": 135876885,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Psoriatic arthritis is a chronic inflammatory disease linked to psoriasis, characterized by joint inflammation, pain, and swelling. Affecting both men and women, typically between ages 30-50, it's driven by rising autoimmune diseases and emerging biologic treatments like TNF and JAK inhibitors. Key market developments include advances in early diagnosis tools and precision medicine, tailoring treatments to genetic profiles. While growth is challenged by high biologic costs and diagnosis complexi",
      "url": "https://finnhub.io/api/news?id=6d6c2f9bc2075c0b32e4585440d25a0af4a43c7f00592f693f00f0d680f64571"
    }
  },
  {
    "ts": null,
    "headline": "What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill",
    "summary": "A steady dose of quality companies will keep your portfolio growing big and strong.",
    "url": "https://finnhub.io/api/news?id=6f77dcacefc94745fb5ff0c50afcfdd618a84e09c61aae803547dbac3a658950",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752220500,
      "headline": "What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill",
      "id": 135877175,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "A steady dose of quality companies will keep your portfolio growing big and strong.",
      "url": "https://finnhub.io/api/news?id=6f77dcacefc94745fb5ff0c50afcfdd618a84e09c61aae803547dbac3a658950"
    }
  },
  {
    "ts": null,
    "headline": "Take Five: Duck and swerve",
    "summary": "July 11 - Tariff curve balls lobbed at economies and markets aroundthe world by U.S. President Donald Trump will punctuate a weekof inflation data from the U.S. and Britain as well as...",
    "url": "https://finnhub.io/api/news?id=3014be0be896208f632895368a86f10913d0e9d67a92a37e7112fe390614c522",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752208332,
      "headline": "Take Five: Duck and swerve",
      "id": 135870996,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "July 11 - Tariff curve balls lobbed at economies and markets aroundthe world by U.S. President Donald Trump will punctuate a weekof inflation data from the U.S. and Britain as well as...",
      "url": "https://finnhub.io/api/news?id=3014be0be896208f632895368a86f10913d0e9d67a92a37e7112fe390614c522"
    }
  }
]